Navigation Links
Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
Date:4/20/2012

CHAPEL HILL, N.C., April 20, 2012 /PRNewswire/ -- There are some two dozen oncology therapies in Phase III testing and many more are in earlier stages of development. While only some of these therapies will make it to launch, those that do will face yet another hurdle: a competitive marketplace where success revolves around planning as much as science.

In this environment, pharmaceutical organizations in the oncology therapeutic area must constantly evaluate which factors play the biggest role in the current launch landscape. One pharma company with promising products in its development pipeline wanted to know what launch success and failure factors play the biggest role in the current launch environment.

To answer this question, Best Practices, LLC conducted a wide-ranging field research project that explores the pivotal success factors and failure points facing new oncology product launches. The research established a critical core set of factors that can make or break a market entry for cancer products as well as other types of therapies.

The study, Success Factors and Failure Points in Oncology Product Launches, presents a framework for launch success:

  • The ability to differentiate
  • A defined target patient population
  • Investment in launch activities
  • Engagement of thought leaders
  • Education of key stakeholders
  • Demonstration of value
  • Utilization of new technologies
  • Avoidance of launch pitfalls

In terms of educating and winning support from key stakeholders, the study found that companies need to focus on different constituents during three critical early periods in a product's lifecycle (Market Entry, Win Share and Grow Share).

When entering the market, oncology launch leaders said companies need to focus on educating KOLs and payers; when trying to win share, the focus shifts to KOLs and specialists; and when trying to grow market share, it's important to focus on specialists and policymakers/government.

The 173-page report examines each of the key issues that are part of the framework for launch success and offers launch leaders two perspectives: an oncology segment and a total benchmark class segment that includes other therapeutic areas. In addition to delivering qualitative and quantitative insights on each aspect of this launch framework, the report presents launch leaders' perspectives on the current and future risk levels for an array of pitfall factors that can affect a launch.

To download a complimentary study excerpt, go to: http://www3.best-in-class.com/re1905.htm.

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 44 managers and executives at 38 leading bio-pharma companies participated in the survey.  In-depth interviews were conducted with leaders from six organizations.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Cepheid Reports 2012 First Quarter Results
3. New Report - Computed Tomography (CT) Market is Expected to Reach USD 5.6 Billion Globally in 2017: Transparency Market Research
4. Sotera Wireless Reports FDA Clearance of ViSi Mobile™ System
5. Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2
6. Solta Medical to Report First Quarter 2012 Results Release and Host Conference Call on May 1
7. Pharmos Corporation Reports First Quarter 2012 Results
8. Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations
9. NxStage® to Report First Quarter Fiscal 2012 Financial Results
10. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
11. Assured Pharmacy Reports Results for the Fiscal Year 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
Breaking Medicine News(10 mins):